Novonesis A/s Class B · OMXCOP:NSIS_B

Novonesis A/s Class B — Novozymes — Non-Deal Roadshow (August 2019)

58 slides from Novonesis A/s Class B's roadshow presentation, Aug 8, 2019

  1. Slide 1: Roadshow presentation 1H 2019

    Roadshow presentation 1H 2019 Released on August 8, 2019

  2. Slide 2: Table of contents

    Table of contents Latest results 3 Overview and strategy 14 Market overview 25 Household Care 26 Food & Beverages 31 Bioenergy 36 Agriculture & Feed 40 Technical & Pharma 45 Sustainability 46 Financials and governance 50 22

  3. Slide 3: Latest results

    Rethink Tomorrow “ee ti i ie NA / ; aN soyozymes ;

  4. Slide 4: Highlights

    Highlights Second-quarter improvement, but overall 1H’19 2019 Key financials Realized Outlook disappointing 1H performance. 2H Sales growth, organic -3% 1-3% acceleration confirmed. EBIT margin 30.0% 28-29% • Agriculture & Feed, Bioenergy and Food & Beverages Net profit growth 1% 3-8% negatively aff

  5. Slide 5: Organic sales growth by geography

    Organic sales growth by geography North America 34%of sales Europe, the Middle East & Africa 37% of sales 1H y/y: -4% 1H y/y: 1% Q2 y/y: -3% Q2 y/y: 0% Developed Emerging 67% (1H 2019: 0% y/y) 33% Latin America 9% of sales (1H 2019: -8% y/y) Asia Pacific* 20% of sales 1H y/y: -3% 1H y/y: -9% Q2 y/y:

  6. Slide 6: Household Care

    Household Care 33% of sales First-half performance as expected • Organic sales growth of minus 2% y/y in 1H 2019 1H y/y organic sales growth • Weakness in the Middle East due to economic 4% distress • Continued trend of growth with regional customers 1% being offset by decline with global customers

  7. Slide 7: Food & Beverages

    Food & Beverages 29% of sales Weak start to the year • Organic sales growth of minus 2% y/y in 1H 2019 1H y/y organic sales growth • Baking down due to economic distress in the 8% Middle East and price declines in freshkeeping 5% 4% • Starch down due to wet weather in the US and Will be updated 3% h

  8. Slide 8: Bioenergy

    Bioenergy 19% of sales Market volatility impacts performance • Organic sales growth of minus 4% y/y in 1H 2019 1H y/y organic sales growth • Wet weather in the US Midwest and low producer 14% margins 7% • E15 approved for all-year sales but limited impact 2% in 2019 • Continued capacity expansion in

  9. Slide 9: Agriculture & Feed

    Agriculture & Feed 13% of sales Feed improving, BioAg impacted by wet weather in the US Midwest 1H y/y organic sales growth • Organic sales growth of minus 6% y/y in 1H 2019 19% • BioAg decline somewhat mitigated by improved Feed performance 1% 3% • Wet weather in the US Midwest negatively impacted

  10. Slide 10: Eight new launches; three for the broad market

    Eight new launches; three for the broad market Innova® Force Innova® Fit Fortiva® New enzymatic offering to Further expansion of the Next-generation yeast from meet demand for better yeast platform, enabling Novozymes yield and temperature penetration of Latin America robustness Latest results • Ove

  11. Slide 11: Financials

    Financials Financials as expected given weak top-line 1H’18 1H’19 performance Key financials Realized Realized Sales growth, organic 4% -3% • Organic sales growth of minus 3% y/y in 1H 2019 • US Midwest and emerging-market softness created headwinds, EBIT margin 28.1% 30.0% impacting Agriculture & F

  12. Slide 12: Financials – 2019 outlook

    Financials – 2019 outlook Full-year outlook maintained after June 6 update 1H’19 2019 Outlook Key financials Realized August 8* • Full-year outlook maintained on all parameters, with organic growth accelerating in second half Sales growth, organic -3% 1-3% • EBIT margin adjusted for one-offs expecte

  13. Slide 13: Summary

    Summary Better Second-quarter improvement, but disappointing 1H business performance. Acceleration expected in 2H with biology • Weaker-than-expected start to the year due to wet weather in the US Midwest and softness in some emerging markets – revised outlook issued on June 6 • Second-quarter perfo

  14. Slide 14: Overview and Strategy

    Rethink Tomorrow Overview and Strategy | | : » bis ex : NM soyozymes

  15. Slide 15: World leader in Bioinnovation - Novozymes at a glance

    World leader in Bioinnovation - Novozymes at a glance Solid financials (2018) Market leader 17 years of innovation driven growth • ~28% EBIT margin (2018) DKKm • ~48% of total market with DKK • ~24% ROIC (2018) 14.3bn in sales (2018) • ~5x EBIT (since IPO) 30% 16,000 • ~3x Sales (since IPO) • ~7x Ne

  16. Slide 16: Uniquely diversified group creating synergies and opportunities

    Uniquely diversified group creating synergies and opportunities Household Care Food & Bioenergy Agriculture & Feed Technical & Organic growth Beverages Organic growth Organic growth Pharma 19% 19% Organic growth Organic growth 13% 11% 12% 9% 9% 7% 6% 4% 5% 5% 5% 4% 2% 2% 3% 2% 1% 1% 0% 2014 2015 201

  17. Slide 17: Our global business serves a lot of local markets and industries

    Our global business serves a lot of local markets and industries North America 34% Europe, the Middle East & 36% of ’18 sales Africa of ’18 sales Sites: Production, R&D Main markets: Bioenergy, HHC, F&B, Sites: HQ, Production R&D BioAg Main markets: HHC, F&B, Feed Acc CAPEX: ~DKK 4.3bn Acc CAPEX: ~

  18. Slide 18: Competitive advantages across the value chain

    Competitive advantages across the value chain has led to a unique market leading position Sustainability • Sustainability is in our DNA helping our customers to save an estimated 88 million tons of CO2 (2018) • Triple bottom line • Pioneering life cycle assessment documentation Scale • Production: 5

  19. Slide 19: Enzyme technology improves Novozymes’ profitability

    Enzyme technology improves Novozymes’ profitability Novozymes dedicates 10-15% of R&D spend to productivity improvement programs 3 ways to gain productivity improvements Purification Raw materials Fermentation Enzymes Formulation Micro-organisms Improve production strain Optimize industrial producti

  20. Slide 20: Better business with biology

    Better business with biology Focus areas Differentiate to succeed Invest in impact Spearhead new business Adapt our approach to fit industry Show up for our customers with Unfold high-potential impact areas potential and concentrate on strong commercial teams, capable in a dynamic, efficient process

  21. Slide 21: Differentiate to succeed with assigned roles for each industry

    Differentiate to succeed with assigned roles for each industry Development seed Fueling mid-term growth but still evolving New strategic opportunity Contributing to long-term growth Growth star Every industry Fueling short-term growth plays an with sharp focus on execution important role Value creat

  22. Slide 22: Invest in impact by focusing the R&D pipeline

    Invest in impact by focusing the R&D pipeline Before Better business with biology Value Value New strategic opportunities Risk Risk Project resource allocation Project resource allocation *Illustrative example 22 Latest results • Overview and strategy • Market overview • Sustainability • Financials

  23. Slide 23: Broader technology offerings increase opportunities over time

    Broader technology offerings increase opportunities over time Past Present Future Enzymes Enzymes Enzymes Microbes Microbes 23 Latest results • Overview and strategy • Market overview • Sustainability • Financials and governance

  24. Slide 24: Spearhead new business in areas of global need

    Spearhead new business in areas of global need Contaminant removal Human oral and gut health Specialty alternative proteins Protecting water resources by Increasing health and Feeding the world by providing applying biological solutions wellbeing with clinically alternative specialty protein to remo

  25. Slide 25: Market overview

    Rethink Tomorrow ” a \(\/ Hf = oe? ex : soyozymes

  26. Slide 26: Household Care overview

    Household Care overview Key industry trends Product launches (2018) Organic growth • Growth in the liquid and unit dose • Licheninase – A new +9% +4% +1% +2% 0% market, driven by consumer enzyme launched for convenience and stronger automatic dishwashing, Sales in commercial focus on these targeting

  27. Slide 27: Our enzyme technology adds significant benefits

    Our enzyme technology adds significant benefits Eliminate Remove stains, Decrease dose, Preserve fabric Save energy, Deal with complex harsh chemicals boost whiteness increase performance texture, color water, time hygiene issues 27 Latest results • Overview and strategy • Market overview • Sustaina

  28. Slide 28: Lifestyle changes are increasing the demand for freshness

    Lifestyle changes are increasing the demand for freshness, and we are on track to deliver DKK 1bn Freshness Urbanization Synthetics Malodor Grime Key consumer concerns identified by Cold wash Detergent Body soils Novozymes format Consumers’ lifestyle changes are …which center around issues the drive

  29. Slide 29: Large potential for future enzyme inclusion in emerging markets

    We see large potential for future enzyme inclusion, especially in emerging markets Emerging markets Significant up-dosing and penetration potential in emerging markets in Presence and emerging market solutions general and Asia Pacific in particular to unlock potential • Innovation hubs in China, Ind

  30. Slide 30: Biological detergents: enzymes can contribute even more

    Biological detergents: We believe enzymes can contribute even more to a detergent Biological detergent and to compaction • New and more stable enzymes to replace surfactants • Freshness solutions to reduce Other the need for perfume Perfume • Enzymes to replace polymer Other functions, such as fabri

  31. Slide 31: Food & Beverages overview

    Food & Beverages overview Key industry trends Product launches Organic growth • Consumer focus on health, wellness (2018) +4% +5% +2% +9% +5% and natural products • Palmora® – Our first • Increase in raw material costs and solution for the palm oil industry Sales in focus on production process DKKm

  32. Slide 32: Better food for a growing world

    Better food for a growing world Trends Opportunities EM industrialization More with less New substrate Productivity streams and yield More natural foods, Health Freshness Health, safety please and taste and sustainability 32 Latest results • Overview and strategy • Market overview • Sustainability •

  33. Slide 33: The grain value chain

    The grain value chain • Significant presence in starch - industry leaders in enzymatic starch conversion for sweeteners • Portfolio that includes LpHera®, Extenda®, Secura® and Sweetzyme® • Frontia® opens a new segment with our starch customers in wet milling, enhancing the yield of key value stream

  34. Slide 34: Enzymatic applications for vegetable oil processing show huge potential

    Enzymatic applications for vegetable oil processing show huge potential New agro- processing applications End products • Cooking oil • Margarine & shortenings • Novozymes offers multiple • CBE solutions across the value • OPO, etc. chain 3 Specialty fats producer • Low trans fat Specialty oils & fat

  35. Slide 35: Increasing consumer health awareness drives food trends

    Increasing consumer health awareness drives food trends and opportunities Healthy food trends Trans fats and Acrylamide enzymatic removal interesteri- fication Low Less sugar Plant lactose added protein Source: Novozymes revenue estimates 35 Latest results • Overview and strategy • Market overview •

  36. Slide 36: Bioenergy overview

    Bioenergy overview Key industry trends Product launches (2018) Organic growth • Growing calls for lower CO2 • Innova® Drive – Novozymes’ first launch within yeast for +19% -5% -3% +11% +12% emissions in the transportation sector, driving conventional biofuels. demand for ethanol Innova® Drive is aim

  37. Slide 37: Bioenergy - a lot of opportunities exist

    Bioenergy - a lot of opportunities exist Ramping up +1bn GPY commercially in EUROPEAN UNION emerging markets Total additional GPY by 2030 Renewable Energy Directive Production: 1.4bn GPY to be ready for 24bn Potential addition: +1bn gallons by 2030 expected shift (gallons per year) +13bn GPY CHINA E

  38. Slide 38: Ethanol production

    Ethanol production Global ethanol production (billion gallons) Ethanol producer margin 28.570 Contribution margin ($/gallon) 25.774 26.182 26.810 2.5 25.083 RoW 23.422 China 2.0 6.860 7.920 EU 1.5 6.760 7.200 6.760 6.267 Brazil 1.0 0.5 13.816 14.313 14.807 15.413 15.936 16.061 NA 0.0 2013 2014 2015

  39. Slide 39: Addressing complexity in bioethanol production

    Addressing complexity in bioethanol production Designing enzymes for individual plants Using our diagnostic program to deliver custom fermentation solutions, tailored to a plant’s unique operating conditions From standard to Past Present Future Basic products for Multiple offerings across Increasing

  40. Slide 40: Agriculture & Feed overview

    Agriculture & Feed overview Key industry trends Product launches (2018) Organic growth • Consumer focus on health, • Acceleron® B-360 ST – A +7% +19% +5% -3% +3% wellness and natural products biological seed treatment that • Sensitivity to fluctuations in promotes symbiosis between microbes and corn

  41. Slide 41: Our new BioAg setup allows for broader outreach

    Our new BioAg setup allows for broader outreach 41

  42. Slide 42: Scientific evidence supports enzyme penetration

    Scientific evidence supports enzyme penetration - enabling livestock farmers to reduce feed cost 70% of total cost of poultry production is feed including additives which is around 5%. Market is sensitive Poultry producer margins are low when: • Feed prices are high to feed and meat • Meat prices ar

  43. Slide 43: Attractive value propositions in feed enzymes

    Attractive value propositions in feed enzymes Phytase Estimated penetration Phosphate • Only 3-30% of phosphate in feed is available to the animal across species • Ronozyme NP® releases half of the phosphate bound – 100% Ronozyme HiPhos® releases nearly all of it • Significant reduction in phosphoro

  44. Slide 44: Committed to core technologies and partnering with industry leaders

    We are committed to our core technologies and partner with industry leaders to win Enzymes Probiotics • Full portfolio of feed enzymes • Growing area for Novozymes with pipeline of products • Recently launched game-changing innovation • Alterion® tracking well • Improve the sustainability of livesto

  45. Slide 45: Technical & Pharma overview

    Technical & Pharma overview Key industry trends Product launches 5 year organic growth • Continuous focus on • BioSec® – Novozymes’ first product for sludge +9% +6% +13% +2% -6% process optimization and dewatering. BioSec® is aimed at municipal cost reduction wastewater treatment • Water scarcity dr

  46. Slide 46: Sustainability

    Rethink Tomorrow ” a \(\/ Hf = oe? ex : soyozymes

  47. Slide 47: Sustainability drives how we do business

    Sustainability drives how we do business CLIMATE WATER PRODUCTION & CONSUMPTION WORLD Limit global warming Ensure clean and Produce more and better By 2030, we will help... increase to 1.5 degrees efficient water use products with less impact 2022 targets Save 60 million tons CO2 Reach > 4 billion p

  48. Slide 48: We plan to continue our journey of operational excellence

    We plan to continue our journey of operational excellence • Novozymes has over time proved how investments in efficiency and optimization programs pay off not only from a sustainability perspective but also from an economic perspective • In the US we have a biogas plant which turns wastewater into s

  49. Slide 49: Remuneration principles for the Executive leadership team

    Remuneration principles for the Executive leadership team Remuneration principles ensure close alignment with long term shareholder interests, links remuneration to shareholder gains and losses, and ensures management retention Annual remuneration scheme Long term incentive program (2017-2019) Salar

  50. Slide 50: Financials and governance

    Rethink Tomorrow Financials and governance “ee ti i ie NA / ; aN soyozymes ;

  51. Slide 51: Historical performance demonstrates track of delivery

    Historical performance demonstrates track of delivery Turnover development Mid-term targets 2020-2022 +5% 14,002 14,142 14,531 14,390 15.000 11,234 11,746 12,459 9.724 10,510 • Organic revenue growth of 5+% DKKm 10.000 5.000 per year 0 (2020 likely impacted by portfolio changes) 2010 2011 2012 2013

  52. Slide 52: Historical performance demonstrates track of delivery

    Historical performance demonstrates track of delivery Net working capital Model assumptions 2020-2022 3.000 2.741 2.768 30% 2.195 NWC/Sales 1.943 2.088 2.023 20% 2.000 1.580 1.720 DKKm 1.076 10% • Improving as % of sales 1.000 0% 0 -10% 2010 2011 2012 2013 2014 2015 2016 2017 2018 NWC to sales (righ

  53. Slide 53: Limited exposure to raw material fluctuations

    Novozymes carries limited exposure to raw material fluctuations Factors impacting COGS Split of Cost of Goods sold • Productivity improvements Raw materials consist primarily of different carbohydrates. • Input prices Approximately 50% of raw material input are e.g., sucrose, maltose, glucose and st

  54. Slide 54: DKK ~20bn returned to shareholders since 2010

    DKK ~20bn returned to shareholders since 2010 5.00 4.50 4.00 3.50 3.00 3.318 3.438 3.062 3.190 2.50 2.925 2.20 1,90 2.000 2.000 2.000 1,60 2.000 2.000 1.519 1.000 832 786 504 400 1.438 1.062 1.190 1.318 687 786 925 504 600 2010 2011 2012 2013 2014 2015 2016 2017 2018 Buyback (DKKm) Dividend (DKKm) D

  55. Slide 55: Shareholder distribution

    Shareholder distribution Two share classes; A and B shares Shareholder distribution of B common stock* • All “B”- shares listed in Copenhagen under the symbol Novo Holdings was the only major stockholder holding more “NZYM B” than 5% of Novozymes common stock • All “A” share capital and 21,991,400 “

  56. Slide 56: Foundation ownership advocates long-term focus

    Foundation ownership advocates long-term focus Purpose of the Foundation Structure and The Novo Nordisk Foundation is an independent Danish ownership foundation with corporate interests. The objective of the Novo Nordisk Foundation is twofold: • To provide a stable basis for the commercial and resea

  57. Slide 57: Our investor relations team

    Our investor relations team Further investor relations information is available from the company homepage at investors.novozymes.com Tobias Björklund Carl Ahlgren Naja Wivel Ulrik Wu Svare Head of Investor relations IR officer Coordinator IR officer +45 3077 8682 +45 3077 2783 +45 3077 2076 +45 3077

  58. Slide 58: Forward-looking statements

    Forward-looking statements This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "bel

Novozymes — Non-Deal Roadshow (August 2019) on 6ix